SecBot SecBot
PRESS-RELEASE ·Filed Mar 27, 2026

ANAB

AnaptysBio, Inc.
MIXED
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Actionable Insight ◆ Mixed

Traders should monitor the April 20, 2026 spin-off date and the execution of the $100M buyback, which could support ANAB stock. The market may re-rate Anaptys as a royalty vehicle, but execution risk around the separation and reliance on external partnerships (GSK, Vanda) remains.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$38.27
T+0 close · Mar 27, 2026 · via day close
Latest settled
+53.87%
T+60 · $58.88
Vs SPY
+37.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $38.27entry
  2. T+1 · 8mo ago −3.50%α −3.14% · $36.93
  3. T+5 · 8mo ago +8.76%α +4.90% · $41.62
  4. T+20 · 7mo ago +74.02%α +61.27% · $66.59
  5. T+60 · 5mo ago +53.87%α +37.80% · $58.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured $80 million in gross proceeds from a $145 million private placement. Concurrently, Anaptys announced a $100 million stock repurchase plan and a lean post-spin-off structure focused on managing royalty assets with minimal operating expenses.

Key Financial Metrics

Deal Value
$80.0M

Key Facts

  • First Tracks Bio raised $80 million in gross proceeds from the sale of 5,791,478 shares at $13.81 per share in a private placement.
  • The spin-off of First Tracks Bio is expected to close on April 20, 2026.
  • Anaptys will retain ~$140–145 million in net cash and investments post-spin-off and operate with less than 10 FTEs and under $10M annual operating expenses.
  • Anaptys announced a $100 million stock repurchase plan effective after March 31, 2026, expiring December 31, 2026.
  • Susannah Gray, former CFO of Royalty Pharma, has been appointed to Anaptys’ board to support its royalty-focused strategy.

Financial Impact

$80 million raised by First Tracks Bio; $100 million buyback authorized by Anaptys; Anaptys to retain $140–145 million in cash and investments

cash positionshare countoperating expensesdilutionequity value

Risk Factors

  • Spin-off may not close as planned, delaying or altering capital return and structure.
  • Anaptys’ future value depends entirely on third-party royalty performance (GSK, Vanda), introducing external execution risk.
  • Limited transparency on how buyback will be executed; could be slow or market-dependent.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 2 press releases from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263788
PRESS-RELEASE Data (Synthetic)press-3263790

Track record

28 reports on ANAB

Performance horizon

10 of 19 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 13 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
  2. Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
  4. Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
  6. Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
  7. Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
  10. Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026